Brief: Virpax Successfully Completes Preclinical Dermal Safety Studies For Epoladerm
18/01/2022 14:17
Jan 18 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O :
* VIRPAX SUCCESSFULLY COMPLETES PRECLINICAL DERMAL SAFETY
STUDIES
FOR EPOLADERM
* VIRPAX - RESEARCHERS CONCLUDED THAT ONCE DAILY DERMAL
ADMINISTRATION OF EPOLADERM FOR 28 DAYS WAS WELL-TOLERATED WITH
NO SERIOUS ADVERSE FINDINGS
Source text for Eikon: ID:nBw5gHq9ta
Further company coverage: VRPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Virpax Pharmaceuticals
See all newsVirpax Pharma plunges as Nasdaq delisting looms
Brief: Virpax Pharmaceuticals Files For Offering On Best Efforts Basis Up To 2.4 Million Shares Of Common Stock
Brief: Virpax receives positive Probudur™ results for dose range study
Brief: Virpax Looking To Use Met To Develop Intranasal Covid Vaccine
Brief: Virpax Confirms Positive Results With Us Army With Probudur™ For Combat Care Study